RECIPIENT PRETRANSPLANT INOSINE MONOPHOSPHATE DEHYDROGENASE ACTIVITY IN NONMYELOABLATIVE HCT
暂无分享,去创建一个
Brian R. Phillips | B. Sandmaier | B. Storer | L. Risler | Joanne Wang | J. McCune | M. Bemer | M. Boeckh | Haichuan Duan | Brianne | S. Raccor
[1] P. Hari,et al. Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trial. , 2013, Biology of Blood and Marrow Transplantation.
[2] Kremena V. Star,et al. Histologic Features in Colon Biopsies Can Discriminate Mycophenolate From GVHD-induced Colitis , 2013, The American journal of surgical pathology.
[3] B. Sandmaier,et al. Nonrelapse mortality and mycophenolic acid exposure in nonmyeloablative hematopoietic cell transplantation. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[4] B. Sandmaier,et al. Population Pharmacokinetics and Dose Optimization of Mycophenolic Acid in HCT Recipients Receiving Oral Mycophenolate Mofetil , 2013, Journal of clinical pharmacology.
[5] Bernhard O. Palsson,et al. The development of a fully-integrated immune response model (FIRM) simulator of the immune response through integration of multiple subset models , 2013, BMC Systems Biology.
[6] B. Sandmaier,et al. A Limited Sampling Schedule to Estimate Mycophenolic Acid Area Under the Concentration‐Time Curve in Hematopoietic Cell Transplantation Recipients , 2012, Journal of clinical pharmacology.
[7] M. Vij,et al. Mycophenolate mofetil-induced colitis with graft versus host disease-like features in a liver transplant recipient. , 2012, Indian journal of pathology & microbiology.
[8] Hong Wang,et al. [Efficacy and safety of low-dose cyclophosphamide plus corticosteroids for type I/II myasthenia gravis]. , 2012, Zhonghua yi xue za zhi.
[9] S. Mineishi. Overcoming the age barrier in hematopoietic stem cell transplantation: progress, but still a long way to go. , 2011, JAMA.
[10] B. Wall,et al. Patterns of injury in mycophenolate mofetil-related colitis. , 2010, Transplantation proceedings.
[11] F. Berthoux,et al. Differential effect of cyclosporine and mycophenolic acid on the human regulatory T cells and TH-17 cells balance. , 2009, Transplantation proceedings.
[12] Jason Y. Park,et al. Mycophenolic Acid (Cellcept and Myofortic) Induced Injury of the Upper GI Tract , 2009, The American journal of surgical pathology.
[13] G. Gerken,et al. Mycophenolic Acid Impedes the Antigen Presenting and Lymph Node Homing Capacities of Human Blood Myeloid Dendritic Cells , 2009, Transplantation.
[14] B. Sandmaier,et al. A Limited Sampling Schedule to Estimate Individual Pharmacokinetic Parameters of Fludarabine in Hematopoietic Cell Transplant Patients , 2009, Clinical Cancer Research.
[15] K. Budde,et al. Improved Assay for the Nonradioactive Determination of Inosine 5'-Monophosphate Dehydrogenase Activity in Peripheral Blood Mononuclear Cells , 2009, Therapeutic drug monitoring.
[16] D. Jain,et al. Spectrum of histologic changes in colonic biopsies in patients treated with mycophenolate mofetil , 2009, Modern Pathology.
[17] P. Martin. Documentation of Engraftment and Characterization of Chimerism Following Hematopoietic Cell Transplantation , 2009 .
[18] Brian R. Phillips,et al. A novel phenotypic method to determine fludarabine triphosphate accumulation in T-lymphocytes from hematopoietic cell transplantation patients , 2009, Cancer Chemotherapy and Pharmacology.
[19] R. Lechler,et al. Conferring indirect allospecificity on CD4+CD25+ Tregs by TCR gene transfer favors transplantation tolerance in mice. , 2008, The Journal of clinical investigation.
[20] J. Parfitt,et al. Mycophenolate Mofetil-related Gastrointestinal Mucosal Injury: Variable Injury Patterns, Including Graft-versus-Host Disease-like Changes , 2008, The American journal of surgical pathology.
[21] A. Kiani,et al. Targeting mycophenolate mofetil for graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation , 2008, Bone Marrow Transplantation.
[22] M. Maris,et al. Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. , 2007, Blood.
[23] N. Le,et al. Regulating regulatory T cells , 2007, Bone Marrow Transplantation.
[24] F. Baron,et al. Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning , 2006, Leukemia.
[25] S. Bergan,et al. Determination of Inosine Monophosphate Dehydrogenase Activity in Human CD4+ Cells Isolated from Whole Blood During Mycophenolic Acid Therapy , 2006, Therapeutic drug monitoring.
[26] H. Deeg,et al. Optimization of allogeneic transplant conditioning: not the time for dogma , 2006, Leukemia.
[27] M. Maris,et al. Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[28] H. Deeg,et al. A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[29] R. Storb,et al. Kinetics of engraftment following allogeneic hematopoietic cell transplantation with reduced-intensity or nonmyeloablative conditioning. , 2005, Blood reviews.
[30] K. Budde,et al. Pre‐Transplant Inosine Monophosphate Dehydrogenase Activity is Associated with Clinical Outcome After Renal Transplantation , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[31] J. Radich,et al. Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. , 2004, Blood.
[32] S. Heimfeld,et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. , 2003, Blood.
[33] M. Raab,et al. Influence of mycophenolic acid on inosine 5'-monophosphate dehydrogenase activity in human peripheral blood mononuclear cells. , 2002, Clinica chimica acta; international journal of clinical chemistry.
[34] K. Budde,et al. Non-radioactive determination of inosine 5'-monophosphate dehydro-genase (IMPDH) in peripheral mononuclear cells. , 2001, Clinical biochemistry.
[35] R. Ponec,et al. Endoscopic and histologic diagnosis of intestinal graft-versus-host disease after marrow transplantation. , 1999, Gastrointestinal endoscopy.
[36] E D Thomas,et al. 1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.
[37] B. Mitchell,et al. Recombinant human inosine monophosphate dehydrogenase type I and type II proteins. Purification and characterization of inhibitor binding. , 1995, Biochemical pharmacology.
[38] R. Lo,et al. Etiology and outcome of diarrhea after marrow transplantation: a prospective study. , 1994, Gastroenterology.
[39] Y. Natsumeda,et al. Tissue-differential expression of two distinct genes for human IMP dehydrogenase (E.C.1.1.1.205). , 1994, Life sciences.
[40] Y. Natsumeda,et al. Characterization of human type I and type II IMP dehydrogenases. , 1993, The Journal of biological chemistry.
[41] K. Sullivan,et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. , 1991, Seminars in hematology.
[42] G Weber,et al. Two distinct cDNAs for human IMP dehydrogenase. , 1990, The Journal of biological chemistry.
[43] F. Collart,et al. Cloning and sequence analysis of the human and Chinese hamster inosine-5'-monophosphate dehydrogenase cDNAs. , 1988, The Journal of biological chemistry.
[44] P. Neiman,et al. CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.